Concepedia

Author

Y. Baranau

State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical CareORCID

Also Known As

Y. Baranau, Y. V. Baranau, Yauheni Baranau, Yauheni V Baranau, Yauheni V. Baranau, Yauheni Valerievich Baranau

31

Publications

242

Citations

7

H-Index

14

Concepts

All Affiliations

State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical CareCelltrion (South Korea)City Clinical Oncology CenterKyiv City Clinical Oncology CenterCentrum Onkologii
YB

About

Y. Baranau is an author at State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care specializing in cancer therapeutics, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

146

2

Cancer Therapeutics

3

3

146

3

Health Sciences

2

2

131

4

Pathology

1

1

15

5

Surgical Oncology

1

1

12

Y. Baranau

×

5

Publications

198

Citations

5

H-Index

YearCitations

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Justin Stebbing, Y. Baranau, Valeriy Baryash,

The Lancet Oncology

2017

119

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

Francisco J. Esteva, Y. Baranau, V. Baryash,

Cancer Chemotherapy and Pharmacology

2019

31

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

Justin Stebbing, Y. Baranau, V. Baryash,

Breast Cancer Research and Treatment

2021

21

LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Thomas Powles, V. Chistyakov, V. Beliakouski,

Annals of Oncology

2021

15

Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).

Justin Stebbing, Y. Baranau, V. Baryash,

Journal of Clinical Oncology

2017

12

Page 1